ZYKADIA Market Summary

Key Factors Driving ZYKADIA Growth

1. Strong efficacy in first-line ALK-positive NSCLC: ZYKADIA demonstrated substantial clinical benefit in previously untreated ALK-rearranged advanced NSCLC in the Phase III ASCEND-4 study. Median progression-free survival (PFS) was 16.6 months versus 8.1 months with platinum-based chemotherapy, corresponding to a hazard ratio of 0.55. The objective response rate was approximately 73%, with a median duration of response of 23.9 months. These data established ceritinib as an effective targeted option in ALK-positive disease.

2. Activity in patients with brain metastases: CNS disease is a major challenge in ALK-positive NSCLC, and ceritinib has demonstrated intracranial activity. In ASCEND-1, intracranial disease control was observed in 79% of ALK-inhibitor-naïve patients and 65% of previously treated patients with brain metastases; six patients with measurable, previously untreated brain lesions achieved a partial intracranial response. This CNS activity expands the clinical utility of ZYKADIA in a difficult-to-treat subgroup.

3. Established efficacy after crizotinib treatment: ZYKADIA was initially approved for patients with metastatic ALK-positive NSCLC whose disease had progressed on or who were intolerant to crizotinib. In the pivotal study supporting the original approval, 163 patients were evaluated and the independently assessed objective response rate was 44%, with a median response duration of 7.1 months. The later ASCEND-5 Phase III study further demonstrated median PFS of 5.4 months versus 1.6 months with chemotherapy (HR 0.49) in patients previously treated with chemotherapy and crizotinib.

4. Additional evidence in Asian patients supports geographic demand: ALK-positive NSCLC is an important precision-oncology segment in Asian markets. In the Asian subgroup of ASCEND-4, ceritinib produced a median PFS of 26.3 months versus 10.6 months with chemotherapy in treatment-naïve patients, with an estimated 34% reduction in the risk of progression (HR 0.66). Such data can support continued adoption in Asian markets where ALK testing and targeted-treatment availability are expanding.

5. Commercial reach has been supported through regional partnerships: In China, Novartis granted BeiGene rights to market and promote ZYKADIA along with four other Novartis oncology products across designated “Broad Markets.” BeiGene began marketing and promotion of these products in Q1 2022, providing an additional commercial channel for ZYKADIA in China.

6. Long-term clinical experience provides a durable niche, although competition limits growth: ZYKADIA has accumulated extensive clinical evidence across first-line and post-crizotinib ALK-positive NSCLC, including the ASCEND-1, ASCEND-4 and ASCEND-5 programs. However, its commercial upside is constrained by newer-generation ALK inhibitors and increasing competition in ALK-positive NSCLC. Consequently, ZYKADIA's future revenue is more likely to be supported by established use, selected patients and geographic markets than by major expansion of the overall ALK market.

ZYKADIA Recent Developments

Novartis' 2025 product-sales disclosure lists its top 20 products, and ZYKADIA is no longer separately included, indicating that it has become a relatively small/established brand compared with Novartis' major growth products. Novartis reported total continuing-operations sales of $54.53 billion in 2025, up 8% versus 2024, but does not provide a standalone ZYKADIA figure in its current product-sales reporting.

“ZYKADIA Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of ZYKADIA for approved indication like Non-small cell lung cancer; as well as potential indication like Gastrointestinal cancer, Haematological malignancies, Solid tumours, and Thyroid cancer in the 7MM. A detailed picture of ZYKADIA’s existing usage in approved and anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the ZYKADIA for approved and potential indications. The ZYKADIA market report provides insights about ZYKADIA’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current ZYKADIA performance, future market assessments inclusive of the ZYKADIA market forecast analysis for approved and potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of ZYKADIA sales forecasts, along with factors driving its market.

ZYKADIA Drug Summary

ZYKADIA is an orally administered, small-molecule tyrosine kinase inhibitor developed by Novartis that selectively targets anaplastic lymphoma kinase (ALK), thereby inhibiting ALK-mediated signaling pathways involved in the growth and survival of cancer cells. It is primarily used for the treatment of patients with metastatic ALK-positive non-small cell lung cancer (NSCLC), including patients who have progressed on or are intolerant to crizotinib, and has demonstrated antitumor activity against ALK-driven tumors. ZYKADIA is available as capsules and tablets, with the recommended dosage generally administered once daily, with dosing and administration varying by formulation and patient requirements. Common adverse reactions include diarrhea, nausea, vomiting, abdominal pain, decreased appetite, weight loss, fatigue, and elevations in liver enzymes, while serious risks include hepatotoxicity, interstitial lung disease/pneumonitis, QT prolongation, hyperglycemia, and pancreatitis. The report provides ZYKADIA’s sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the ZYKADIA Market Report

The report provides insights into:

• A comprehensive product overview including the ZYKADIA MoA, description, dosage and administration, research and development activities in approved indications like Non-small cell lung cancer; as well as potential indication like Gastrointestinal cancer, Haematological malignancies, Solid tumours, and Thyroid cancer.
• Elaborated details on ZYKADIA regulatory milestones and other development activities have been provided in ZYKADIA market report.
• The report also highlights ZYKADIA‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in approved and potential indications across the United States, Europe, and Japan.
• The ZYKADIA market report also covers the patents information, generic entry and impact on cost cut.
• The ZYKADIA market report contains current and forecasted ZYKADIA sales for approved and potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The ZYKADIA market report also features the SWOT analysis with analyst views for ZYKADIA in approved and potential indications.

Methodology

The ZYKADIA market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

ZYKADIA Analytical Perspective by DelveInsight

• In-depth ZYKADIA Market Assessment

This ZYKADIA sales market forecast report provides a detailed market assessment of ZYKADIA for approved indication like Non-small cell lung cancer; as well as potential indication like Gastrointestinal cancer, Haematological malignancies, Solid tumours, and Thyroid cancer in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted ZYKADIA sales data uptil 2034.

• ZYKADIA Clinical Assessment

The ZYKADIA market report provides the clinical trials information of ZYKADIA for approved and potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

ZYKADIA Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

ZYKADIA Market Potential & Revenue Forecast

• Projected market size for the ZYKADIA and its key indications
• Estimated ZYKADIA sales potential (ZYKADIA peak sales forecasts)
• ZYKADIA Pricing strategies and reimbursement landscape

ZYKADIA Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• ZYKADIA Market positioning compared to existing treatments
• ZYKADIA Strengths & weaknesses relative to competitors

ZYKADIA Regulatory & Commercial Milestones

• ZYKADIA Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

ZYKADIA Clinical Differentiation

• ZYKADIA Efficacy & safety advantages over existing drugs
• ZYKADIA Unique selling points

ZYKADIA Market Report Highlights

• In the coming years, the ZYKADIA market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The ZYKADIA companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence ZYKADIA’s dominance.
• Other emerging products for Non-small cell lung cancer; as well as potential indication like Gastrointestinal cancer, Haematological malignancies, Solid tumours, and Thyroid cancer are expected to give tough market competition to ZYKADIA and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of ZYKADIA in approved and potential indications.
• Analyse ZYKADIA cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted ZYKADIA sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of ZYKADIA in approved and potential indications.

Key Questions

• What is the class of therapy, route of administration and mechanism of action of ZYKADIA? How strong is ZYKADIA’s clinical and commercial performance?
• What is ZYKADIA’s clinical trial status in each individual indications such as Non-small cell lung cancer; as well as potential indication like Gastrointestinal cancer, Haematological malignancies, Solid tumours, and Thyroid cancer and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the ZYKADIA Manufacturers?
• What are the key designations that have been granted to ZYKADIA for approved and potential indications? How are they going to impact ZYKADIA’s penetration in various geographies?
• What is the current and forecasted ZYKADIA market scenario for approved and potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of ZYKADIA in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to ZYKADIA for approved and potential indications?
• Which are the late-stage emerging therapies under development for the treatment of approved and potential indications?
• How cost-effective is ZYKADIA? What is the duration of therapy and what are the geographical variations in cost per patient?